Skip to main content
Emerging Technologies in Therapeutics and Diagnostics
Keira Smith
Expert Analysis
By Waqas Haque, MD, MPH In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on the approval of lifileucel, the first individualized tumor-infiltrating lymphocyte therapy, for advanced melanoma; updates on the EV-302 trial of enfortumab vedotin, an antibody-drug conjugate technology; a new blood test for colorectal cancer screening from Guardant Health; the Model Facts label to guide decisions using machine learning; and more!  
Lifileucel Granted Accelerated Approval for Unresectable or Metastatic Melanoma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) for adult patients with unresectable or metastatic melanoma previously treated with a programmed cell death protein 1 (PD-1) blocking antibody, and if BRAF V600–positive, a BRAF inhibitor with or without a mitogen-activated protein kinase (MEK) inhibitor...
Nivolumab Approved for Adjuvant Treatment of Stage IIB/C Melanoma
Lyn Brook
FDA Updates
The FDA has approved nivolumab (Opdivo®, Bristol Myers Squibb Company) for adjuvant treatment of patients 12 and older with completely resected stage IIB/C melanoma.   Why it matters: "Patients with resected stage IIB/C melanoma are at high risk of recurrence with outcomes similar to patients with resected stage IIIB disease," wrote Dr. Georgi...
Melphalan Approved for Liver-Directed Treatment for Uveal Melanoma
Lyn Brook
FDA Updates
The FDA has approved melphalan for injection (Hepzato Kit™/Hepatic Delivery System), containing melphalan (Hepzato™, Delcath Systems, Inc.) as a liver-directed treatment for patients with uveal melanoma with unresectable hepatic metastases affecting ≤50% of the liver. This treatment is permitted for those with no extrahepatic disease, or extrahepat...
Retifanlimab Granted Accelerated Approval for Metastatic/Recurrent Merkel Cell Carcinoma
Keira Smith
FDA Updates
The FDA has granted accelerated approval to retifanlimab-dlwr (Zynyz™, Incyte), a programmed cell death protein 1 (PD-1)–blocking antibody, for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). "Retifanlimab is a humanized, hinge-stabilized immunoglobulin G4 kappa (IgG4κ) anti–PD-1 monoclonal antibody with sa...
Educational Advancements Made in Treatment of Merkel Cell Carcinoma
Lyn Brook
Practice Patterns
i3 Health has provided a continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma, that enabled the health care team to acquire significant gains in proficiency and knowledge for treating their patients with Merkel cell carcinoma ...
Cemiplimab for Metastatic Basal Cell Carcinoma: Exploring the Data With Karl Lewis, MD
Keira Smith
Expert Analysis
Cemiplimab, a programmed cell death protein 1 (PD-1) inhibitor, was approved in 2021 as the first and only systemic therapy to demonstrate clinical benefit among patients with advanced basal cell carcinoma (BCC) previously treated with hedgehog pathway inhibitor (HHI) therapy. At the American Association for Cancer Research (AACR) Annual Meeting in...
Navigating the Selection of Immunotherapy in Metastatic Melanoma With Benjamin Izar, MD
Lyn Brook
Expert Analysis
Recently, the FDA approved the combination of relatlimab plus nivolumab for patients with unresectable or metastatic melanoma. However, many challenges remain in the selection of patients who will benefit from these agents and in determining alternative options for those who are ineligible for the combination. In this interview in honor of Melanoma...
Combination of Nivolumab and Relatlimab Approved for Unresectable or Metastatic Melanoma
Lyn Brook
FDA Updates
The FDA has approved the combination of nivolumab and relatlimab-rmbw (Opdualag™, Bristol-Myers Squibb) for patients with unresectable or metastatic melanoma. OpdualagTM is a fixed-dose dual immunotherapy combination of nivolumab, a programmed cell death protein 1 (PD-1)–blocking antibody, and relatlimab, a first-in-class human lymphocyte–activatio...